Use of Bone Morphogenetic Protein in Pediatric Cranioplasty With Pre- and Postoperative Radiation Therapy

J Craniofac Surg. 2019 Oct;30(7):e677-e679. doi: 10.1097/SCS.0000000000005761.

Abstract

Introduction: Bone morphogenetic protein (BMP) is a signaling protein that has proven efficacy in the setting of bone repair. It has been widely used in orthopedic surgery and is being implemented more in the field of craniofacial surgery, although there is limited report on its use in pediatric patients.

Case: A 6-year-old female with stage IV neuroblastoma with metastasis to the parietal parasagittal calvarium, which had failed to respond to multiple medical therapies, including radiation therapy. The tumor was excised and the defect was replaced with a combination of split calvarial bone graft and rhBMP-2. The patient received post-operative radiation therapy with no reports of complications of the defect site on immediate and long term follow up.

Conclusion: The use of BMP has the potential to aid in bone generation for high-risk calvarial defects. It can be safe and efficacious to use in the pediatric population; however, future studies should be done to determine the safest and most effective dosing of BMP.

Publication types

  • Case Reports

MeSH terms

  • Animals
  • Bone Morphogenetic Protein 2 / therapeutic use*
  • Bone Transplantation
  • Child
  • Combined Modality Therapy
  • Female
  • Humans
  • Postoperative Period
  • Recombinant Proteins / therapeutic use
  • Skull / surgery*

Substances

  • BMP2 protein, human
  • Bone Morphogenetic Protein 2
  • Recombinant Proteins